Ventipulmin Syrup

This page contains information on Ventipulmin Syrup for veterinary use.
The information provided typically includes the following:
  • Ventipulmin Syrup Indications
  • Warnings and cautions for Ventipulmin Syrup
  • Direction and dosage information for Ventipulmin Syrup

Ventipulmin Syrup

This treatment applies to the following species:
Manufacturer: Boehringer Ingelheim

(clenbuterol HCl)

NADA 140-973, Approved by FDA

For oral use in horses only

Ventipulmin Syrup Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Ventipulmin Syrup Caution

Federal law prohibits the extralabel use of this drug in food animals.

Each mL contains: Clenbuterol HCl 72.5 mcg

Description

Clenbuterol (4-amino-alpha-[(tert-butylamino) methyl]-3, 5-dichlorobenzyl alcohol hydrochloride) is a beta-2-adrenergic agonist which provides bronchodilating properties as well as other effects, with minimum effect on the cardiovascular system. It is provided as a colorless, palatable syrup. Ventipulmin Syrup (clenbuterol hydrochloride) is antagonized by beta-adrenergic blocking agents.

Ventipulmin Syrup Indications

Ventipulmin Syrup (clenbuterol hydrochloride) is indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

Contraindications

Ventipulmin Syrup antagonizes the effects of prostaglandin F2 alpha and oxytocin. Ventipulmin Syrup should not be used in pregnant mares near term. Because tachycardia may occur, Ventipulmin Syrup should not be used in horses suspected of having cardiovascular impairment.

Warning

The effect on reproduction in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended.

Human Warnings: Not for human use. Do not use in horses intended for human consumption. Keep out of the reach of children. In case of accidental ingestion, contact a physician immediately. Ingestion of Ventipulmin Syrup may cause undesirable reactions. Clenbuterol, like other beta adrenergic agonists, can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.

Dosage and Administration

Administer orally twice a day (b.i.d.). Initial dose is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily.

Dosage Schedule:

Initial dosage: administer 0.5 mL/100 lbs (0.8 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 1.0 mL/100 lbs (1.6 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 1.5 mL/100 lbs (2.4 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 2.0 mL/100 lbs (3.2 mcg/kg) for 3 days (6 treatments);

If no improvement, horse is non-responder to clenbuterol and treatment should be discontinued.

Recommended duration of treatment at effective dose is 30 days. At the end of this 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, the 30-day treatment regimen may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated.

Directions for Administration: Remove safety cap and seal; replace with enclosed plastic dispensing cap. Remove cover from dispensing tip and connect syringe (without needle). Draw out appropriate volume of Ventipulmin Syrup. Administer orally to the horse. Replace cover on dispensing tip to prevent leakage.

Dosage Calculation Chart

Lbs. Body Weight

mL/treatment at 0.5 mL/100#
(0.8 mcg/kg)

mL/treatment at 1.0 mL/100#
(1.6 mcg/kg)

mL/treatment at 1.5 mL/100#
(2.4 mcg/kg)

mL/treatment at 2.0 mL/100#
(3.2 mcg/kg)

500

2.5

5.0

7.5

10.0

600

3.0

6.0

9.0

12.0

700

3.5

7.0

10.5

14.0

800

4.0

8.0

12.0

16.0

900

4.5

9.0

13.5

18.0

1000

5.0

10.0

15.0

20.0

1100

5.5

11.0

16.5

22.0

1200

6.0

12.0

18.0

24.0

1300

6.5

13.0

19.5

26.0

1400

7.0

14.0

21.0

28.0

1500

7.5

15.0

22.5

30.0

1600

8.0

16.0

24.0

32.0

1700

8.5

17.0

25.5

34.0

1800

9.0

18.0

27.0

36.0

Administer two treatments per day.

Precaution: The safety cap should be placed on the bottle when not in use.

Adverse Reactions

Mild sweating, muscle tremor, restlessness, urticaria and tachycardia may be observed in some horses during the first few days of treatment. May cause elevated creatine kinase (CK) serum levels. Ataxia was observed in 3 out of 239 horses (1.3%) in clinical studies. To report suspected adverse reactions, to obtain a Material Safety Data Sheet (MSDS), or for technical assistance, call 1-866-638-2226.

How Supplied

Ventipulmin Syrup is available in 100 mL, 330 mL and 460 mL plastic bottles containing 72.5 mcg clenbuterol HCl per mL.

NDC 0010-3017-02 - 100 mL, NDC 0010-3017-03 - 330 mL, NDC 0010-3017-04 - 460 mL

Storage

Store at or below 25°C (77°F). Avoid freezing.

Ventipulmin is a registered trademark of Boehringer Ingelheim Vetmedica GmbH.

Manufactured for: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506 U.S.A

Made in Mexico

Net Contents:

 

100 mL

301701-04

090330770/1

330 mL

301704-04

090330771/1

460 mL

301721-03

090330772/1

NAC No.: 1028113.4

BOEHRINGER INGELHEIM VETMEDICA, INC.
2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506-2002
Telephone:   800-325-9167
Fax:   816-236-2717
Website:   www.bevaccinesmart.com
    www.bi-vetmedica.com
    www.productionvalues.us
    www.prrsresearch.com
    www.thinkmetacam.com
    www.vetera-vaccines.com
    www.vetmedin-us.com
    www.yourdogsheart.com
Email:   info@productionvalues.us
Every effort has been made to ensure the accuracy of the Ventipulmin Syrup information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-09-05

(web2)